A comparative study of efficacy of ilaprazole according to the body mass index in patients with laryngopharyngeal reflux disease

A comparative study of Laryngopharyngeal reflux disease main symptoms improvement according to Body Mass Index (BMI) after administration of Ilaprazole

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004035

Enrollment

Registered

2019-06-04

Start date

2019-07-31

Completion date

Unknown

Last updated

2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The improvement degree of symptoms of laryngopharyngeal reflux disease would be evaluated by using reflux symptom index (RSI) score and same analysis would be performed according to the BMI aft

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Men or women above 18 years of age and having symptoms of laryngopharyngeal reflux disease that has lasted more than a month (2) Those with above 13 and 7 score in reflux symptom index (RSI) and reflux finding score (RFS) of laryngopharyngeal reflux disease (3) Those who heard the explanation of this clinical trial and decide to participate voluntarily and sign the consent form

Exclusion criteria

Exclusion criteria: (1) The highly sensitive person to proton pump inhibitor including ilaprazole (2) Those with the history of malignant tumor of the larynx (3) Those with need to take steroids or aspirin(more than 325mg/d), warfarin, coumarin during this study constantly (4) Those who has undergone surgery or treatment for gastroesophageal reflux disease or gastric acid suppression surgery or gastro-duodenal surgery (5) Those who has undergone major surgery affecting gastric acid secretion (6) Psychiatric patient, alcohol addictor or those with the history of drug abuse (7) Pregnant and lactating women (8) Childbearing women (Menopausal women who are amenorrheic for at least 12 months are considered to be non-childbearing women.) (9) Those who participated in other clinical trial within 6 months before screening (10) Those with observed preneoplastic lesions or neoplastic lesions in pharynx or larynx (11) Those who are judged to be improper for this clinical trial

Design outcomes

Primary

Measure	Time frame
Reflux finding score (RFS)	—

Secondary

Measure	Time frame
Reflux symptom index (RSI)	—

Countries

Korea, Republic of

Contacts

Public ContactDongjin Lee

Hallym University Medical Center-Kangnam

leeresidency@gmail.com+82-2-829-5217

Outcome results